Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.48 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1922860 | 1.00 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2C9HPGDHTT | |
| Hydrochloric Acid SCHEMBL11771194 | 0.98 | CYP1A2 (0.54) | CYP1A2CYP2C19CYP2C9HPGDHTT | |
| SCHEMBL110689 | 0.98 | CYP1A2 (0.58) | CYP1A2CYP2C19CYP2C9HPGDHTT | |
| SCHEMBL29484446 | 0.98 | CYP1A2 (0.58) | CYP1A2CYP2C19CYP2C9HPGDHTT | |
| Iodide SCHEMBL19990736 | 0.95 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2C9HPGDHTT | |
| Ammonia Solution, Strong SCHEMBL9173309 | 0.95 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2C9HPGDHTT | |
| SCHEMBL20593911 | 0.95 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2C9HPGDHTT | |
| Bromide SCHEMBL22401521 | 0.95 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2C9HPGDHTT | |
| Iodide SCHEMBL28994517 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP2C19CYP2C9HPGDHTT | |
| Dimethylamine SCHEMBL28254662 | 0.89 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2C9HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848336-A1 | METHOD FOR MANUFACTURING HOLLOW METAL NANOPARTICLES, AND HOLLOW METAL NANOPARTICLES MANUFACTURED THEREBY | LG Chem, Ltd. (KR) | 2015-03-18 | — | — | EP | claimed |
| WO-2009114695-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2009-09-17 | — | — | WO | claimed |
| EP-1915139-A1 | NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN | Elan Pharma International Limited (IE) | 2008-04-30 | — | — | EP | claimed |
| WO-2008010784-A1 | NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2008-01-24 | — | — | WO | claimed |
| US-20070264348-A1 | Nanoparticulate fibrate formulations | ELAN PHARMA INTERNATIONAL, LTD. | 2007-11-15 | — | — | US | claimed |
| US-6976647-B2 | System and method for milling materials | ELAN PHARMA INTERNATIONAL, LIMITED (IE) | 2005-12-20 | — | — | US | claimed |
| US-20050107366-A1 | Spin trapping pharmaceutical compositions and methods for use thereof | CARNEY JOHN M (US) | 2005-05-19 | — | — | US | claimed |
| US-20050019412-A1 | Novel glipizide compositions | ELAN PHARMA INTERNATIONAL LIMITED | 2005-01-27 | — | — | US | claimed |
| US-20040164194-A1 | System and method for milling materials | ELAN PHARMA INTERNATIONAL LIMITED | 2004-08-26 | — | — | US | claimed |
| EP-0223157-B1 | IMPROVED AUTOFLUOROGRAM COMPOSITION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-01-31 | — | — | EP | claimed |
| EP-0223157-A1 | Improved autofluorogram composition | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-27 | — | — | EP | claimed |
| CN-112055581-B | Ultrasound-induced drug delivery system using drug carrier comprising nanobubbles and drug | 三育大学校产学协力团 | 2023-04-07 | — | — | CN | disclosed |
| CN-115802770-A | Method for efficiently passivating lead iodide-rich wide-band-gap perovskite by using pure-chlorine two-dimensional perovskite and solar cell thereof | 华侨大学 | 2023-03-14 | — | — | CN | disclosed |
| WO-2023013834-A1 | HEAT SINK PAINT COMPOSITION, PREPARATION METHOD THEREFOR, HEAT SINK COATING FILM FORMED THEREFROM, AND HEAT SINK COMPRISING SAME | 퓨어만 주식회사 | 2023-02-09 | — | — | WO | disclosed |
| CN-110636837-B | Pharmaceutical composition of CYP17 inhibitor and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-0409617-A2 | Thiolactams, process for their preparation and use as biocides | ZENECA LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
| EP-0223157-B1 | IMPROVED AUTOFLUOROGRAM COMPOSITION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-01-31 | — | — | EP | disclosed |
| US-4710319-A | Autofluorogram composition | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0223157-A1 | Improved autofluorogram composition | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-27 | — | — | EP | disclosed |
| US-4202882-A | TETRAAZO FUSED HETEROCYCLE AND QUATERNARY AMMONIUM COMPOUND | POLYCRAFT LABORATORIES, INC., A CORP. OF NJ. | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107366-A1 | Spin trapping pharmaceutical compositions and methods for use thereof | PPOX, TXN2, TXN | CA2 4846/4885HTR2A 2374/4885CYP1A2 1203/4885 |
| US-20050019412-A1 | Novel glipizide compositions | DPP4, GID4, SLC5A2 | CA2 514/4885HTR2A 845/4885CYP1A2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.